Summary
PAF-acether (1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) has been implicated in a variety of inflammatory and ischaemic disorders (e.g., myocardial ischemia, anaphylactic shock). Recently, the peptide leukotrienes (i.e., LTC4, LTD4) have been shown to mediate the increase in coronary vascular resistance induced by PAF-acether in the isolated perfused rat heart. In isolated perfused guinea pig hearts, PAF-acether produced a dose-dependent increase in coronary perfusion pressure (CPP) and a decrease in contractile force (CF). At 50 μmol/l, PAF increased CPP by 13 ± 3 mm Hg and decreased CF by 47 ± 12% in 8 hearts. Radioimmunoassay of the coronary effluent did not detect peptide leukotrienes or thromboxane B2 (TxB2) in response to PAF. Addition of a specific PAF-acether receptor antagonist, CV-6209 (25 nmol/l), blocked the increase in coronary perfusion pressure and decrease in contractile force. OKY-1581 (400 nmol/l), a thromboxane synthetase inhibitor or LY-171,883 (7.3 μmol/l) a leukotriene D4 receptor antagonist, failed to prevent the increase in CPP or the decrease in CF. These data indicate that the PAF-acether induced increase in CPP is not mediated by the peptide leukotrienes or thromboxane A2 (TxA2). Possible mechanisms for the increase in CPP induced by PAF-acether in the isolated perfused guinea pig heart include a direct receptor mediated constriction of coronary resistance vessels, release of a non-eicosanoid coronary constrictor as a mediator of the response, or via enhancement of coronary microvascular permeability.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aharony D, Dobson P, Bernstein PR, Dusner EJ, Krell RD, Smith JB (1983) A radioimmunoassay for peptide-leukotrienes. Determination of SRS-A release from guinea pig lungs. Biochem Biophys Res Commun 117:574–579
Alloatti G, Montrucchio G, Marino F, Tetta C, De Paulis R, Morea M, Emanuelli G, Camussi G (1986) Effect of platelet-activating factor (PAF) on human cardiac muscle. Int Arch Allergy Appl Immun 79:108–112
Benveniste J, Boullet C, Brink C, Labat C (1983) The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br J Pharmacol 80:81–83
Benveniste J, Henson PM, Cochrane CG (1972) Leukocyte-dependent histamine release from rabbit platelets; the role of IgE, basophils and a platelet activating factor. J Exp Med 136: 1356–1377
Benveniste J, Roubin R, Chignard M, Jouvine-Marche E, LeCouedic JP (1982) Release of platelet-activating factor (PAF-acether) and 2-lyso-PAF-acether from three cell types. Agents Actions 12:711–713
Benveniste J, Vargaftig BB (1983) Platelet-activating factor: an ether lipid with biological activity. In: Mangold HK, Paltauf F (eds) Ether lipids: biochemical and biomedical aspects. Academic Press, New York, p 355
Bessin P, Bonnet J, Apfel D, Soulard C, Desgroux L, Pelas I, Benveniste J (1983) Acute circulatory collapse caused by platelet-activating factor (paf-acether) in dogs. Eur J Pharmacol 86:403–410
Bjork J, Lindbom L, Gerdin B, Smedegard G, Arfors KE, Benveniste J (1983) PAF-acether (platelet activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. Acta Physiol Scand 119:305–308
Braquet P, Vargaftig B (1986) Pharmacology of platelet activating factor. Transplant Proc (Suppl 4) 18:10–19
Camussi G, Aglietta M, Malavasi F, Tetta C, Piacibello W, Sanavio F, Bussolino F (1983) The release of platelet-activating factor from human endothelial cells in culture. J Immunol 131:2397–2403
Cerrina J, Raffestin B, Labat C, Boullet C, Bayol A, Gateau O, Brink C (1983) Effects of Paf-acether on isolated muscle preparations from the rat, guinea-pig and human lung. In: Benveniste J, Arnoux (eds) Platelet-Activating Factor INSERM Symposium No. 23. Elsevier Science Publishers, pp 205–212
Etienne A, Hecquet F, Soulard C, Spinnewyn B, Clostie F, Braquet P (1985) In vivo inhibition of plasma protein leakage and salmonella enteritidis-induced mortality in the rat by a specific paf-acether antagonist: BN 52021. Agents Actions 17:368–370
Ezra D, Feuerstein G, Ramwell PW, Hayes E, Goldstein RE (1985) Effects of platelet-activating factor on coronary hemodynamics and coronary venous plasma levels of TxB2, 6-Keto-PGFα, and Leukotriene C4 immunoreactivity in the intact domestic pig heart. Adv Prost Thromb Leuk Res 13:19–21
Feuerstein N, Ramwell PW (1981) OKY-1581, A potential selective thromboxane synthetase inhibitor. Eur J Pharmacol 69:533–534
Heffner JE, Shoemaker SA, Canham EM, Patel M, McMurtry IF, Morris HG, Repine JE (1983) Platelet-induced pulmonary hypotension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2. Chest 83:78–85
Hsueh W, Crussi FG, Arroyave JL (1986) Release of norepinephrine in platelet activating factor (PAF)-induced bowel necrosis. The role of sulfidopeptide leukotrienes. Second International Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids. Gatlinburg, TN (abstract) p 75
Humphrey DM, McManus LM, Hanahan DJ, Pinckard RN (1984) Morphological basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine. Lab Invest 50:16–25
Humphrey DM, McManus LM, Satouchi K, Hanahan DJ, Pinckard RN (1982) Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab Invest 46:422–431
Lefer AM, Müller HF, Smith JB (1984) Pathophysiological mechanisms of sudden death induced by platelet activating factor. Br J Pharmacol 83:125–130
Lefer DJ, Lefer AM (1986) Failure of endothelium to mediate potential vasoactive action of platelet activating factor (PAF). IRCS Med Sci 14:356–357
Levi R, Burke JA, Zhao-Gui G, Hattori Y, Hoppens CM, McManus LM, Hanahan DJ, Pinckard RN (1984) Acetyl glyceryl ether phosphorylcholine (AGEPC): A putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res 54:117–124
Lewy RI, Wiener L, Walinsky P, Lefer AM, Silver MJ, Smith JB (1980) Thromboxane release during pacing-induced angina pectoris: Possible vasoconstrictor influence on the coronary vasculature. Circulation 61:1165–1171
McManus LM, Pinckard RN, Fitzpatrick FA, O'Rourke RA, Crawford MH, Hanahan DJ (1981) Acetyl glyceryl ether phosphorylcholine. Intravascular alterations following intravenous infusion into the baboon. Lab Invest 45:303–310
Mojarad M, Hamasaki Y, Said SI (1983) Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema. Bull Eur Physiopathol Resp 19:253–258
Olson MS, Buxton DB, Fisher RA, LaPointe D, Hill C (1986) AGPEC: a potent agonist of hepatic metabolism. Second International Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids. Gatlinburg, TN (abstract) p 76
Pinckard RM, McManus LM, Hanahan DJ (1982) Chemistry and biology of acetyl glyceryl ether phosphorylcholine (platelet-activating factor). In: Weissmann G (ed) Advances in inflammation research, vol 4. Raven Press, New York, pp 147–180
Piper PJ, Stewart AG (1986) Coronary vasoconstriction in the rat isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4. Br J Pharmacol 88:595–605
Roth DM, Lefer DJ, Lefer AM (1985) Effects of peptide leukotrienes on cardiac dynamics in rat, cat and guinea pig hearts. Am J Physiol 249:H477-H484
Saeki S, Masugi F, Ogihara T, Otsuka A, Kunahara Y, Watanabe K, Tamura K, Adashi A, Kmagai A (1985) effects of 1-O-alkyl-2-sn-glycero-3-phosphorycholine (platelet activating factor) on cardiac function in perfused guinea-pig heart. Life Sci 37:325–329
Stahl GL, Lefer AM (1987) Heterogeneity of vascular smooth muscle responsiveness to lipid vasoactive mediators. Blood Vessels 24:24–30
Stahl GL, Lefer AM (1986) Mechanisms of platelet activating factor induced cardiac anaphylaxis in the isolated perfused rat heart. Circulation 74:11–355
Terashita Z, Imura Y, Takatani M, Tsushima S, Nishikawa K (1987) CV-6209 — A high potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Therap 242:263–268
Zimmerman GA, McIntyre TM, Prescott SM (1985) Production of platelet-activating factor by human vascular endothelial cells: evidence for a requirement for specific agonists and modulation by prostacyclin. Circulation 72:718–727
Author information
Authors and Affiliations
Additional information
Supported by Research Grant No. HL-25575 from the National Heart, Lung and Blood Institute of the NIH
NIH Predoctoral Trainee (HL-07599)
Summer Research Fellow
Send offprint requests to A. M. Lefer
Rights and permissions
About this article
Cite this article
Stahl, G.L., Lefer, D.J. & Lefer, A.M. PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig heart. Naunyn-Schmiedeberg's Arch Pharmacol 336, 459–463 (1987). https://doi.org/10.1007/BF00164883
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00164883